On May 18, 2022 Accelerating Cancer Immunotherapy Research (ACIR) has featured Immunetune’s presentation during the Cancer Immunotherapy (CIMT) (Free CIMT Whitepaper) Annual Meeting 2022 held May 10-12 in Mainz, Germany (Press release, ImmuneTune, MAY 18, 2022, View Source [SID1234614789]). At CIMT (Free CIMT Whitepaper), our CSO Jeroen van Bergen presented new preclinical results on our neoantigen cancer vaccine in combination with checkpoint inhibitors.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

ACIR’s mission is to accelerate the advancement of cancer immunotherapy by providing, free-of-charge and readily accessible on the internet, a weekly synopsis of the key advances in this fast moving and multifaceted field.

On May 18, 2022 Bavarian Nordic A/S (OMX: BAVA) reported that the share buy-back program, which was announced and initiated on May 9, 2022, has now been terminated, as the intended number of shares under the program has been repurchased (Press release, Bavarian Nordic, MAY 18, 2022, View Source [SID1234614823]). The program was executed in accordance with the provisions of Regulation (EU) No. 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse and supplementing Regulation (EU) 2016/1052 of 8 March 2016, which together constitute the Safe Harbour Regulation. The purpose of the program was to meet the Company’s obligations arising from the share-based incentive program for the Board of Directors and Executive Management.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Under the program Bavarian Nordic A/S has bought back 71,562 shares, cf. the table below:

Transaction date Number of shares Average purchase price, DKK Transaction Value, DKK

The details for each transaction made under the share repurchase program have been attached to this announcement.

With the transactions stated above, Bavarian Nordic A/S owns a total of 146,330 own shares, corresponding to 0.21% of the share capital. The total amount of shares in the company is 70,472,935 including treasury shares.

On May 18, 2022 The companies Atonco (Nantes-Saint Herblain, France) and IONETIX Corporation (Lansing, MI) reported that they have signed a partnership agreement to ensure the radioisotope production and supply of the radiopharmaceutical necessary for the success of Atonco’s clinical studies and commercialization in the United States (Press release, IONETIX, MAY 18, 2022, View Source [SID1234614839]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Atonco, a radiopharmaceutical company at the clinical stage, aims to demonstrate through its clinical research program the relevance of a breakthrough therapeutic treatment, alpha immunotherapy, targeting superficial bladder cancer.

IONETIX Corporation operates a North American good manufacturing practice ("GMP") manufacturing and supply chain of positron and alpha-emitting radiopharmaceuticals. Ionetix through this agreement will produce astatine-211 and manufacture patient doses for clinical use, according to CGMP regulations. The agreement includes the supply of the radioisotope, astatine-211, the GMP manufacturing of the injectable doses and specifies the terms of the U.S. FDA agent agreement signed in August 2021.

IONETIX is leading the way by establishing the first North American commercial scale supply of astatine-211, from its new cyclotron facility in Lansing, MI that is dedicated to the production and distribution of alpha-emitting radioisotopes. "We are very excited about the partnership with Atonco which will enable us to fully support their clinical development program and commercialization in the United States, subject to FDA approval of Atonco’s drug candidates", declared David Eve, Vice President of Medical Affairs.

"This partnership agreement is a key step in the development of Atonco", declared Sylvain Fanier, President of Atonco. "We are convinced that Ionetix is the most reliable and advanced partner to ensure optimal sourcing for our clinical development and commercialization in North America. Thanks to their expertise and experience in the manufacture of radiopharmaceuticals and in discussions with the FDA, Ionetix will greatly contribute to our common success, in order to offer patients suffering from bladder cancer a very promising therapeutic alternative".

On May 18, 2022 Caladrius Biosciences, Inc. (Nasdaq: CLBS) ("Caladrius" or the "Company"), a clinical-stage biopharmaceutical company dedicated to the development of innovative therapies designed to treat or reverse disease, reported that David J. Mazzo, Ph.D., President and Chief Executive Officer of Caladrius, will present a corporate overview at the H.C. Wainwright Global Investment Conference being held both virtually and in-person at the Fontainebleau Miami Beach Hotel in Miami, FL on May 23-26, 2022 (Press release, Caladrius Biosciences, MAY 18, 2022, View Source [SID1234614927]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Dr. Mazzo’s presentation will be delivered in-person and is scheduled for Wednesday, May 25, 2022 at 9:30 a.m. Eastern time. For more information on the conference and how to register, please contact your H.C. Wainwright representative or visit www.hcwevents.com/globalconference.

On May 18, 2022 Defence Therapeutics Inc. ("Defence" or the "Company"), a Canadian biopharmaceuticals company primarily focussed on the development of novel immune-oncology vaccines and drug delivery technologies, is pleased to reported the development of novel dual-acting AccumTM-linked protein vaccine, AccuVAC-PTE7, dedicated to protect from cervical cancer (prophylactic vaccine) or to treat (therapeutic vaccine) patients with pre-established cervical tumors (Press release, Defence Therapeutics, MAY 18, 2022, View Source [SID1234626249]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The protection from cervical cancer can currently only be achieved with the use of Gardasil-9 or Cervarix, two vaccines directed against the L1 proteins of HPV. However, there is currently no cure for patients with established cervical cancer and the clinical trials conducted previously with other companies with both the E6 and E7 proteins were highly disappointing.

Since the AccumTM molecule was previously shown to significantly enhance the immunogenicity of various proteins, the Defence team engineered a novel protein-based vaccine targeting the oncogenic protein E7 normally used by HPV to transform healthy cells into an outgrowing tumor. Pre-clinical studies conducted on this new vaccine, AccuVAC-PTE7, not only provide a 100% protection from cervical cancer if delivered prophylactically (e.g. before tumor growth), but also show potent anti-tumoral effects against established tumors when combined with various immunecheckpoint blockers such as anti-PD-1, anti-CTLA4 or anti-CD47.

"The idea of having a dual-acting vaccine targeting cervical cancer capable of both protecting and treating patients from cervical cancer is a giant step in the field of cancer vaccines. In addition, this vaccine contains a single protein, the E7, which makes it easier to manufacture and use compared to a mix of 9 proteins as provided by the Gardasil-9 product", says Mr. Plouffe, the CEO of Defence Therapeutics.

According to Fortune Business Insights, the global HPV vaccine market size was valued at $3.80 Bn in 2019 & is projected to reach $12.69 Bn by 2027, with a CAGR of 16.3%